QCM
REGN icon

QRG Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

QRG Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Sell
620
-82
-12% -$55.8K ﹤0.01% 941
2026
Q1 		$542K Sell
702
-82
-10% -$62.8K 0.01% 754
2025
Q4 		$605K Sell
784
-28
-3% -$19K 0.01% 700
2025
Q3 		$457K Sell
812
-1,170
-59% -$662K 0.01% 752
2025
Q2 		$1.04M Sell
1,982
-2,202
-53% -$1.23M 0.01% 597
2025
Q1 		$2.65M Sell
4,184
-16,527
-80% -$11.4M 0.03% 402
2024
Q4 		$14.8M Sell
20,711
-2,469
-11% -$2.07M 0.15% 135
2024
Q3 		$24.4M Buy
23,180
+1,040
+5% +$1.16M 0.26% 87
2024
Q2 		$23.3M Buy
22,140
+638
+3% +$618K 0.28% 74
2024
Q1 		$20.7M Buy
21,502
+985
+5% +$937K 0.26% 91
2023
Q4 		$18M Buy
20,517
+369
+2% +$304K 0.27% 87
2023
Q3 		$16.6M Buy
+20,148
New +$15.8M 0.29% 83

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

QRG Capital Management's REGN Position: Q2 2026 in Review

QRG Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $55.8K and leaving 620 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #941.

QRG Capital Management first reported a position in REGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $24.4M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • QRG Capital Management held 620 shares of Regeneron Pharmaceuticals worth $387K as of Q2 2026.
  • QRG Capital Management sold 82 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $55.8K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of QRG Capital Management's portfolio in Q2 2026, its #941 holding.
  • QRG Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • QRG Capital Management's Regeneron Pharmaceuticals position peaked at $24.4M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.